Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OncoSec Medical Inc ONCSQ

Healthcare Biotechnology
OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec... see more

Recent & Breaking News (GREY:ONCSQ)

Vista Partners Updates Coverage on OncoSec Medical (Ticker: ONCS); Price Target $1.20

Marketwired May 6, 2015

OncoSec Medical to Present at Prominent Scientific and Investment Conferences in May

PR Newswire May 4, 2015

Vista Partners Publishes April 2015 Macroeconomic & Investment Newsletter

Marketwired April 8, 2015

OncoSec Medical to Present at Needham & Company's 14th Annual Healthcare Conference

Business Wire April 2, 2015

OncoSec Medical CEO Punit Dhillon to Host Live Webinar to Provide Corporate Update and 2015 Outlook

Business Wire March 17, 2015

OncoSec Medical Announces Six Months Results for Fiscal Year End 2015

Business Wire March 12, 2015

OncoSec Medical to Present at Prominent Scientific and Investment Conferences in March

Business Wire March 4, 2015

Heat Biologics, Inc. and OncoSec Medical Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms

GlobeNewswire February 18, 2015

OncoSec Medical Inc. and Heat Biologics, Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms

Business Wire February 18, 2015

OncoSec Medical to Present at Two Events in February

Business Wire February 3, 2015

Vista Partners Initiates Coverage on OncoSec Medical (Ticker: ONCS); Price Target $1.20

Marketwired January 13, 2015

OncoSec Medical Obtains Allowance of Key Patent Application for Intratumoral Delivery of Plasmid IL-15

Business Wire January 13, 2015

OncoSec Medical Plans to Initiate Pilot Study in Triple Negative Breast Cancer

Business Wire January 12, 2015

OncoSec Medical to Present at Three Events in January

Business Wire January 7, 2015

OncoSec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse

Business Wire December 9, 2014

OncoSec Medical Announces First Quarter Results for Fiscal Year End 2015

Business Wire December 8, 2014

OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate Patient-Selection Biomarker in Immunotherapy

Business Wire December 2, 2014

OncoSec Medical to Present at Two Events in December

Business Wire November 28, 2014

Nature Publication Co-Authored by Robert H. Pierce, Chief Scientific Officer, OncoSec Medical

Business Wire November 26, 2014

UC San Francisco and OncoSec Medical Collaborate to Evaluate Investigational Combination of ImmunoPulse and Anti-PD-1 Treatment

Business Wire November 25, 2014